Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 1, January, p. 45–56

doi: 10.17219/acem/67561

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

IL-6, IL-1β, and TNF-α only in combination influence the osteoporotic phenotype in Crohn’s patients via bone formation and bone resorption

Martina Blaschke1,A,C,D,E,F, Regine Koepp1,B,C,E,F, Julia Cortis1,B, Marina Komrakova2,E,F, Matthias Schieker3,E,F, Ute Hempel4,E,F, Heide Siggelkow1,A,B,C,D,E,F

1 Clinic of Gastroenterology and Gastrointestinal Oncology, Göttingen University Medical Center, Germany

2 Department of Trauma Surgery and Reconstructive Surgery, Göttingen University Medical Center, Germany

3 Experimental Surgery and Regenerative Medicine, Department of Surgery, Ludwig-Maximillians-University (LMU), Munich, Germany

4 Institute of Physiological Chemistry, Medical Faculty Carl Gustav Carus, Dresden University of Technology, Germany


Background. Crohn´s disease (CD) is associated with a higher prevalence of osteoporosis. The pathogenesis of bone affliction remains controversial, especially if inflammatory cytokines or glucocorticoid therapy are the main contributors. In postmenopausal osteoporosis, bone resorption is induced by IL-6, IL-1β and TNF-α. In contrast, in children with CD, IL-6 exclusively decreased bone formation without affecting bone resorption.
Objectives. The objective of this study was to further clarify the pathophysiology of bone affliction in adult patients with CD with the use of an osteoblast and osteoclast cell model.
Material and Methods. Inflammatory cytokines IL-6, IL-1β, and TNF-α were measured in adult CD patients’ serum. Mean values of these cytokines were applied with or without dexamethasone to the human cell line SCP-1 (osteoblastic cell model). Also, the effect of cytokines on primary human osteoclast differentiation and activity was determined.
Results. The combined cytokine application increased the receptor activator of NF-κB ligand/osteoprotegerin (RANKL/OPG) ratio 2-fold after 2 and 14 days. Additional application of dexamethasone to SCP-1 cells further increased the RANKL/OPG ratio 3-fold, but decreased IL-6 and IL-1β expression to 10% and 50%, respectively. TNF-α expression was maximally suppressed to 16% by dexamethasone in the presence of cytokines. In osteoclasts, the combined cytokine treatment decreased expression of characteristic genes to approx. 30%, while increasing osteoclast resorption activity to 148%. In addition, a cytokine stimulated osteoblast cell culture-generated supernatant stimulated osteoclast resorption activity by 170%.
Conclusion. Our results suggest that IL-6, IL-1β, and TNF-α only in combination induced osteoclaststimulating activity represented by the RANKL/OPG ratio in osteoblasts. Dexamethasone further increased this effect in osteoblasts, while decreasing cytokine expression. The results in osteoclasts support a direct and osteoblast-mediated effect on bone resorption. Our in vitro results differentiate for the first time the effect of cytokines on bone turnover as measured in adult CD patients from the additional dexamethasone effect on osteoblasts as part of the pathophysiology of osteoporosis.

Key words

cytokines, osteoprotegerin, Crohn’s disease, bone remodeling, RANK ligand

References (42)

  1. Compston JE, Judd D, Crawley EO, et al. Osteoporosis in patients with inflammatory bowel disease. Gut. 1987;28:410–415.
  2. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease: A population-based cohort study. Ann Intern Med. 2000;133:795–799.
  3. Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis. Gut. 2000;46:176–181.
  4. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn’s disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1–10.
  5. Compston JE. Review article: Osteoporosis, corticosteroids and inflammatory bowel disease. Aliment Pharmacol Ther. 1995;9:237–250.
  6. Sylvester FA, Wyzga N, Hyams JS, Gronowicz GA. Effect of Crohn’s disease on bone metabolism in vitro: A role for interleukin-6. J Bone Miner Res. 2002;17:695–702.
  7. Stevens C, Walz G, Singaram C, et al. Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci. 1992;37:818–826.
  8. Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94:174–181.
  9. Pacifici R. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res. 1996;11:1043–1051.
  10. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science. 1992;257:88–91.
  11. Seck T, Diel I, Bismar H, Ziegler R, Pfeilschifter J. Expression of interleukin-6 (IL-6) and IL-6 receptor mRNA in human bone samples from pre- and postmenopausal women. Bone. 2002;30:217–222.
  12. Deal C. Bone loss in rheumatoid arthritis: Systemic, periarticular, and focal. Curr Rheumatol Rep. 2012;14:231–237.
  13. Trouvin AP, Goeb V. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: Maintaining the balance to prevent bone loss. Clin Interv Aging. 2010;5:345–354.
  14. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo). 2013;2013:125705.
  15. Roodman GD. Role of cytokines in the regulation of bone resorption. Calcif Tissue Int. 1993;53(Suppl 1):S94–98.
  16. Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn’s disease. Eur J Gastroenterol Hepatol. 2009;21:159–166.
  17. Varghese S, Wyzga N, Griffiths AM, Sylvester FA. Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr. 2002;35:641–648.
  18. Mori T, Miyamoto T, Yoshida H, et al. IL-1beta and TNFalpha-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis. Int Immunol. 2011;23:701–712.
  19. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn’s disease. Am J Gastroenterol. 2005;100:2031–2035.
  20. Best WR, Becktel JM, Singleton JW, Kern F, Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
  21. Siggelkow H, Cortis J, Claus C, et al. Erythrocyte sedimentation rate as an osteoporosis risk factor in patients with active Crohn’s disease. Osteology. 2009;18:209–216.
  22. Boker W, Yin Z, Drosse I, et al. Introducing a single-cell-derived human mesenchymal stem cell line expressing hTERT after lentiviral gene transfer. J Cell Mol Med. 2008;12:1347–1359.
  23. Lutter AH, Hempel U, Wolf-Brandstetter C, et al. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. J Cell Biochem. 2010;109:1025–1032.
  24. Siggelkow H, Schmidt E, Hennies B, Hufner M. Evidence of downregulation of matrix extracellular phosphoglycoprotein during terminal differentiation in human osteoblasts. Bone. 2004;35:570–576.
  25. Ponce ML, Koelling S, Kluever A, et al. Coexpression of osteogenic and adipogenic differentiation markers in selected subpopulations of primary human mesenchymal progenitor cells. J Cell Biochem. 2008;104:1342–1355.
  26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402–408.
  27. Blaschke M, Giesen M, Baums M, et al. Differential expression of ostoblast related genes in mesenchymal progenitor cells induced by serum of patients with active Crohn’s disease with and without osteoporosis. J Stem Cells Regen Med. 2007;2:47–48.
  28. Vihinen MK, Kolho KL, Ashorn M, Verkasalo M, Raivio T. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol. 2008;159:693–698.
  29. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn’s disease, but not in ulcerative colitis, at diagnosis. Gastroenterology. 1994;107:1031–1039.
  30. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:1895–1902.
  31. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol. 2011;300:G191–201.
  32. Kondo T, Kitazawa R, Yamaguchi A, Kitazawa S. Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels. J Cell Biochem. 2008;103:335–345.
  33. de Kruif MD, Lemaire LC, Giebelen IA, et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia. J Immunol. 2007;178:1845–1851.
  34. Reinisch W, Gasche C, Tillinger W, et al. Clinical relevance of serum interleukin-6 in Crohn’s disease: Single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol. 1999;94:2156–2164.
  35. Andus T, Gross V, Casar I, et al. Activation of monocytes during inflammatory bowel disease. Pathobiology. 1991;59:166–170.
  36. Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13:1379–1384.
  37. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005;54:479–487.
  38. Algate K, Haynes DR, Bartold PM, Crotti TN, Cantley MD. The effects of tumour necrosis factor-alpha on bone cells involved in periodontal alveolar bone loss; osteoclasts, osteoblasts and osteocytes. J Periodontal Res. 2015.
  39. Moon SJ, Ahn IE, Jung H, et al. Temporal differential effects of proinflammatory cytokines on osteoclastogenesis. Int J Mol Med. 2013;31:769–777.
  40. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factors alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol. 1987;138:775–779.
  41. Stashenko P, Obernesser MS, Dewhirst FE. Effect of immune cytokines on bone. Immunol Invest. 1989;18:239–249.
  42. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: Emerging insights into the pathophysiology of osteoporosis. N Engl J Med. 1995;332:305–311.